Physician profile
Cara Mccandless
NPI 1063463255
$1,108.41
in general payments reported to CMS, 2019-2025
18 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.01 · 2020: $12.48 · 2022: $130 · 2023: $248 · 2024: $279 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $287.09 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $126.83 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $114.89 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $103.65 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $51.69 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $51.39 | 2020-2025 | Spravato |
| Corium, LLC | $51.33 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $47.13 | 2023-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.31 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $44.13 | 2022 | |
| Neurocrine Biosciences, INC. | $38.75 | 2025 | |
| Tris Pharma INC | $30.28 | 2022-2023 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.94 | 2025 | |
| Indivior INC. | $21.67 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $21.39 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.67 | 2025 | Uzedy |
| Lundbeck LLC | $15.16 | 2023 | Rexulti |
| Allergan, INC. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Mccandless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.